South Australian pharmaceuticals company Mayne Pharma reshuffled its board and reduced its size last week, sending shares in the firm down slightly over the five trading days.

Chair Frank Condella has retired after just over four years in the seat, while non-executive directors Patrick Blake and Anne Lockwood will step down from the board following the release of the company’s half year results in February.

The company said the reduction of the board’s size was “in the best interests of the company”.

Meanwhile, Professor Bruce Robertson – a director of heavyweight health companies Cochlear and CS Pharmaceuticals – was appointed non-executive chair of the board.

You might like

Business

Corporate Ladder: your weekly guide to executive appointments in South Australia

Business

Briefcase: Business snippets from around South Australia

For Mayne Pharma, the changes follow a tumultuous 2025 during which it was subject to a $672 million takeover by US-based Cosette.

That deal was blocked by the Australian Treasurer in November after the Foreign Investment Review Board found the deal was not in the national interest.

Elsewhere, Mayfield Group fell alongside news that major shareholder Ellerston Capital reduced its stake in the business.

Koonenberry Gold led the Losers list despite announcing positive drilling results at its Hand to Hand Project in New South Wales.

Gold, silver and critical minerals explorers dominated the Winners list, reflecting global trends.

This included Resolution Minerals posting “ultra-high grade” antimony and silver drilling results from its Horse Heaven project in Idaho, USA.

The full list of Winners and Losers for the week ending January 16:

Data via Baker Young Limited analysts.